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Background: Gout is a chronic, inﬂammatory arthritis characterized by painful and debilitating acute/
episodic ﬂares. Until recently, gout has been regarded as a minor medical problem, in part because theKey words:
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associated economic burden has not been appreciated. Previous literature on this subject focused on the
costs associated with acute episodes of gout rather than on the long-term medical and economic
implications of this chronic disorder.
Objective: Our aim was to estimate the current impact of gout in the United States with respect to
disability and economic costs.
Methods: The following data sources were used: published data on the incremental economic burden of
gout; statistics from the US Census Bureau and the US Bureau of Labor Statistics; and recent
epidemiological and clinical literature concerning the course, treatment, and outcomes of the disease.
Disability is expressed as days of lost productivity. Charges for gout-related treatments were used as
direct cost inputs.
Results: Gout affects an estimated 8 million Americans, among whom those working have an average of
almost 5 more absence days annually than workers without gout. On average, the incremental annual
cost of care for a gout patient is estimated at 4$3000 compared with a nongouty individual. Even
though comorbidities common in gout patients account for a portion of this increased economic burden,
the total annual cost attributable to gout patients in the United States is likely in the tens of billions of
dollars and comparable to those of other major chronic disorders, such as migraine and Parkinson’s
disease.
Conclusions: The economic burden of gout is most readily assessable in patients whose acute arthritic
ﬂares result in emergency department visits, bedridden days, and episodic loss of productivity. Chronic
progression of the disease can also result in long-term impairment of function and health-related quality
of life, but the contribution of chronic gout to the economic burden is more difﬁcult to quantitate because
gout is frequently associated with serious cardiovascular, metabolic, and renal comorbidities. Recent
demonstration that successful gout management can reverse functional deﬁcits in many chronic gout
patients, however, supports the views that chronic gout contributes substantially to the medical and thus
economic costs of these patients and that early and aggressive efforts to improve gout outcomes are
likely to reduce the associated economic burden.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Gout does not readily come to mind when one mentions the
most costly and feared diseases. People correctly think about
cardiovascular diseases, cancer, asthma, and depression, amongr Inc.
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Open access under CC BY-NC-ND liceothers. The traditional recognition of gout as a disease of the
wealthy and inﬂuential1 has likely constrained public concern with
this disorder, which, because of limited therapeutic options, has
until recently also been regarded by the medical community as
“unexciting.”
Recent years have, however, witnessed a re-emergence of
interest in gout and its management and costs as topics important
to the medical care system. Reasons for renewed interest in gout
include increases in the incidence and prevalence of gout, which is
now estimated to affect 48 million Americans; recognition of
suboptimal long-term gout patient outcomes due, in part, to an
inadequate range of therapeutic options and poor use of even
these; acquisition of new knowledge about mechanisms under-
lying expression of the disease; and novel therapeutic initiativesnse.
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the potentially chronic progressive and disabling features of gout.2
These changes in the gout arena, although portending more
effective therapy than has previously been available, necessarily
come with costs in research, education, pharmaceutical/biological
development, and delivery that deserve consideration. Assessments
of the era of gout pharmacotherapy limited to generic nonsteroidal
anti-inﬂammatory drugs, unbranded (and unapproved but never-
theless marketed) colchicine, and allopurinol have shown gaps in
the effectiveness and safety delivered. The new initiatives have
underscored the needs for educating providers in the optimal use of
the available agents and for expediting development of new
therapeutic agents. In the past 3 years, the US Food and Drug
Administration has reviewed for marketing approval at least 4 new
gout agents, 2 of which have been approved (febuxostat and
pegloticase), thus surpassing its activity in gout for the past 45 years.
If the world of health care was a rational one, resources devoted
to individual diseases would be related to their respective burdens
of illness. That is not the case. As we are aware, for example,
patients and their families can advocate successfully for research
and investment in diseases of their speciﬁc interest. We read about
campaigns to ﬁght breast cancer or to conquer HIV/AIDS and hear
public service messages about diet and exercise to prevent diabetes
and heart disease, but we do not hear about gout walks, gout
parades, gout day, or gout associations. Clearly, the burden of gout
is less visible than that of many other medical problems. This may
be because most patients affected by gout are 50 years or older,
more often (but not universally) male, and afﬂicted at great
frequency with 1 or more of the serious comorbid diseases
discussed in the following. Additionally, the natural history of gout
usually follows a slow course, characterized initially by acute
intermittently disabling ﬂares or attacks, which, in the absence of
appropriate uric acid management, evolve to a high risk for
progression to chronic pain and physical impairment and increas-
ing economic burden. Many gout patients are thus trying to live
with their gradually diminishing health-related quality of life and
functional status and, in this setting of multiple illnesses, gout (like
cataracts or benign prostate enlargement) is often viewed as a
bothersome condition, warranting little attention in its early stages
because it seems unlikely to compromise the battle for survival.
Gout is a painful and disabling inﬂammatory arthritis accom-
panied by hyperuricemia, deﬁned as a serum uric acid (urate) level
exceeding urate solubility in body ﬂuids. Serum urate levels
exceeding 6.8 mg/dL (400 mmol/L) impart a risk for urate crystal
formation and deposition in tissues, which can incite the acute
inﬂammatory responses that characterize acute gouty arthritic
attacks and chronic inﬂammation that support silent but massive
deposition of urate crystals in a ﬁbrous tissue background that
characterizes the gouty tophus. Many individuals experiencing a
ﬁrst acute gout attack (40%–60%) experience a second attack
within 1 year3 and increasingly frequent, prolonged, and more
severe attacks occur over the years in the majority of gout patients.
Tophaceous lesions develop in many untreated gout patients that
can cause a chronic erosive and deforming arthritis (gouty
arthropathy) and similar damage to bones, tendons, bursas, skin,
and even solid organs. Recurrent gout attacks, chronic arthropathy,
and tophi are, in many instances, directly responsible for chronic
pain, functional impairment for work and activities of daily living,
and compromised health-related quality of life. The role of gout in
these severe outcomes is demonstrated by substantial improve-
ment and/or reversal in these symptoms and signs when long-
term reduction and maintenance of subsaturating serum urate
levels are achieved with urate-lowering therapy.4,5
The incidence and prevalence of gout have increased signiﬁ-
cantly in recent decades, especially among older patients of both
sexes. Gout is now estimated to affect 48 million Americans.6,7It is important to appreciate that gout has the potential to progress,
over years, from a disease of episodic acute ﬂares to one of chronic
disability (with or without persistent ﬂares). It is also critical to
recognize the distinction between medications aimed at reducing
the pain and disability of acute attacks (anti-inﬂammatory agents,
such as nonsteroidal anti-inﬂammatory drugs, colchicine, and corti-
costeroids) and those used to reverse hyperuricemia (urate-lowering
agents, such as allopurinol, febuxostat, pegloticase, and uricosuric
drugs). Anti-inﬂammatory agents do not lower urate levels, and
currently available urate-lowering agents do not have anti-
inﬂammatory properties; nevertheless, appropriate use of these
2 classes of medication (alone or in combination) is paramount in
achieving the management aims of prompt alleviation of painful
gout ﬂares, prevention of ﬂare recurrences, and prevention or
reversal of disease progression. Success in achieving these aims is
associated with improved quality of life and physical function.4,5
It is a reasonable, although, to date, unproved, hypothesis that
successful long-term management should reduce the ﬁnancial
burden of gout, which, as discussed in the following, is substan-
tially greater than has been documented. That is, prevention and
reversal of the symptoms and signs of gout, aims increasingly
attainable in an era of renewed interest and an expanding
therapeutic armamentarium, very likely will mitigate the high
costs associated with poorly controlled and progressive gout.
A potential impediment to an accurate estimate of the overall
ﬁnancial burden of gout is the well-established association of both
hyperuricemia and gout with a number of important comorbid
diseases, including hypertension, cardiovascular disease, metabolic
syndrome, and chronic kidney impairment. In fact, hyperuricemia
and gout are established risk factors (although not necessarily
causal risk factors) for these disorders, each of which carries a high
disease burden for patient’s physical and societal ﬁnancial well-
being. In this setting, it is often difﬁcult to attribute with certainty
the costs of health care in the individual to one of several
coexisting diseases. It is signiﬁcant, then, that in a recent study4
of patients with severe and advanced gout refractory to standard
oral urate-lowering therapy, maintenance of serum urate levels
well within the subsaturating range during treatment with a
urate-lowering biological agent demonstrated signiﬁcantly
improved outcomes with regard to pain, physical function, and
health-related quality of life, symptoms that might a priori have
been attributed to their multiple associated diseases.
With this background, including the number of affected persons,
the costs and capabilities of treatment regimens, the limited number
of studies looking at the burden of gout and the difﬁculties of making
precise attributions of cost, it remains appropriate to take a fresh look
at the economic burden of gout, starting with what is known to date.Methods
A literature search was conducted using PubMed, Embase, and
Cochrane Reviews to identify articles pertaining to gout disease
burden and associated costs of chronic gout. Records were
reviewed manually to identify the most relevant studies pertaining
to the objective of this article. In addition, bibliographies of
retrieved articles were screened to identify additional sources of
information. Estimates from the US Census Bureau and the US
Bureau of Labor Statistics were used to quantify disability
expressed as days of lost productivity. Charges for gout-related
treatments were used as direct cost inputs.
Results
The most cited work looking at the burden of gout estimated
annual gout-related treatment costs for patients newly diagnosed
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2002, before the availability of newer treatments and revised
recommendations for the use of traditional therapies and only
included incident cases of gout in men who experienced their ﬁrst
ﬂare. In addition, with evidence that the incidence rate of primary
gout has recently increased 2-fold over 2 decades,6,7 it seems likely
that the costs associated with even this small subset of gout
patients (reported in 2003) would be substantially greater by
2013. In a 2008 study, Wu et al9 controlled for confounding
comorbid conditions and found that gout patients cost $3038 more
annually than patients without gout, and Khanna et al10 recently
reported that the cost of medical care is as high as $25,000 annually
for each individual with severe gout (≥6 attacks per year) and
$18,000 per year per person with 3 acute attacks annually. In
contrast, individuals without gout in this study were reported to
average total health care costs of $5000 per year.10
In 2002, gout was reported to account for an estimated 3.9million
annual ambulatory care visits (69% to primary care physicians and
o5% to rheumatologists).11 A recent study looking at data from
2006 to 2008 found that gout-related visits accounted for 0.7% of all
emergency department visits, with an annual cost in 2008 of $166
million.12 Data collected from 2001 to 2004 in an employed
population showed that annual health care costs to employers were
$3165 higher for an employee with gout than for one without
($6870 vs $3705).12 Costs were higher for medical claims, sick leave,
prescription drugs, short-term disability, and workers’ compensation
beneﬁts.13 In addition, and as described in the following, employees
with gout have more absence days annually for all categories of
health-related work absence than those without gout.14
Using the recently reported estimate of 48 million gout patients
in the United States,7 the gout patient overall annual medical care
costs reported by Wu et al,9 and the $3165 difference between the
cost of care for those patients with and without gout in 2006,13 the
overall aggregate annual costs for the medical care of gout patients
may have exceeded $20 billion in 2006; it is clear that overall
aggregate annual costs for the medical care of gout patients
exceeded $20 billion. To achieve accuracy in estimating the costs
directly attributable to gout, it is, of course, necessary to adjust the
annual costs for gout patient care to exclude costs incurred by
comorbid diseases highly prevalent among gout patients. There is,
however, no information available to determine with reliability the
magnitude of this adjustment. Nevertheless, even if, conservatively,
only 20% of the economic burden of gout patient care is directly
associated with gout, a $4 billion direct cost of gout-related patient
care is clearly not a minor problem.
In addition, indirect costs of gout add to the burden of this
disease. Lynch et al13 found an increasing relationship between
number of gout attacks and short-term disability and absence days.
Brook et al14 and Kleinman et al15 report that employed gout patients
on average have almost 5 more work absence days annually than
employees without gout. The US labor force consisted of 155 million
persons in July 2012.16 If gout is present in 2% of workers (3.1 million
persons) and each misses 5 days annually as a result of the disease,
the yearly loss of wages/productivity amounts to $833 per worker
(based on 2010 data17) or an aggregate loss of $2.6 billion. Thus, a
combined provisional estimate of annual direct and indirect costs of
gout patient care totals 4$6 billion. In fact, the actual disease burden
is even greater when the cost and health risks of over-the-counter
analgesic and anti-inﬂammatory drugs, the missed wages of spouses,
and the need for caregivers or transport providers are added.Discussion
For reasons given earlier, a precise ﬁgure for the economic
burden of gout remains elusive; nevertheless, our minimumestimate for annual costs exceeding $6 billion is substantially
greater than previously appreciated. The high and increasing
prevalence of gout and considerable clinical impact (both direct
and related to urate crystal deposition and indirect in the form of
association with important comorbidities) have raised both pro-
fessional and public attention to the disease and made it a
signiﬁcant health concern. The nature of the link of gout and
hyperuricemia to important and costly other cardiovascular, met-
abolic, and renal diseases remains to be clariﬁed and is an
important contemporary public health concern.18–20
Our provisional estimate of the economic burden of gout is
based on the limited published data on the subject over several
decades, publicly available health care and health economics data,
and recent epidemiological and clinical evidence pertaining to
disease course and prevalence, comorbid associations, and con-
temporary therapeutic recommendations. Key questions to be
resolved are the extent to which successful control of the hyper-
uricemia of gout can relieve symptoms and signs of the disease
and what impact such treatment may have on the course of the
morbidities with which gout is associated. Answers to these
questions should shed light on the important and currently
uncertain issue of how much of the disabilities and costs associ-
ated with care of gout patients are directly attributable to or
causally related to gout rather than to associated morbid proc-
esses. Until such questions are addressed, it is unlikely that
accurate and satisfying estimates of the burden of gout illness will
be achieved. Thus, we make a rather conservative estimate of the
burden of gout in the hope of amplifying interest in this disease
that has received little attention until the past decade.
Although we believe the provisional estimate of gout economic
burden presented in this study is a reasonable and very conserva-
tive approximation and more closely describes the current sit-
uation than previously appreciated, there are some limitations to
this work. We used secondary data sources incorporating several
time periods. In addition, gout patients still in the work force may
be underproductive or some may have left the work force
altogether; as a result, the total cost of gout may be signiﬁcantly
higher, given the reduced productivity. As pointed out at length,
distribution of costs for gout patient care to gout as opposed to
comorbid diseases is not evidence based; we regard our choice to
ascribe only 20% of the cost of gout patient care to gout as quite
conservative; if, in fact, the proportion of costs for direct gout care
is greater, then we have underestimated the ﬁnancial burden of
gout. Finally, we did not include costs associated with nonwork
activities, the signiﬁcant impact on quality of life, or the impact of
rare but costly life-threatening events such as severe cutaneous
reactions associated with allopurinol use.21Conclusions
Patients with gout have signiﬁcant direct and indirect costs
associated with their disease. Urate crystal burden associated with
gout results in both increasing levels of disability and attacks that
signiﬁcantly impair health-related quality of life and physical
function. Strategies for improving patient outcomes while decreas-
ing the economic burden of gout to managed care, employers, and
insurers are desirable.
Identiﬁable areas where an improvement can be made to
reduce costs are as follows: Prescribing optimal treatments for the management of acute
attacks, preventive treatment for recurrent attacks, and ini-
tiating treatment for reversal of hyperuricemia in gout
patients at an earlier stage of the disease than is typically
done today.
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noncompliance is one of the causes of progression to chronic
gout and therefore higher costs. Updating the efﬁcacious use of long-available treatment strat-
egies, such as with allopurinol, is good. However, the develop-
ment of novel, highly selective therapies for controlling
hyperuricemia and alleviating gouty inﬂammation are indi-
cated for speciﬁc patient populations. These new therapies will
be especially helpful for patients with extensive or advanced
comorbidities, which often limit efﬁcient use of traditional gout
treatment. It is a reasonable goal to raise awareness in primary care
physicians, who see most gout patients, about the newest
therapies and guidelines and to increase their skills in enhanc-
ing drug-regimen compliance in their patient populations. In
this way, progression of gout to more severe and costly stages
might be prevented or avoided.Acknowledgments
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